Barriers to accessing essential medicines for kidney disease in low- and lower middle–income countries|
Anna Francis(Children's Health Queensland Hospital and Health Service), Vivekanand Jha(The George Institute for Global Health), Sabine Karam(American University of Beirut), Udeme E. Ekrikpo(University of Uyo), Nikhil Pereira-Kamath, Titi Chen(Westmead Hospital), Robert Kalyesubula(Africa Center), Eranga Wijewickrama(University of Colombo), Michelle Wong(University of British Columbia), Viviane Cálice-Silva(Universidade da Região de Joinville), Elliot Koranteng Tannor(Kwame Nkrumah University of Science and Technology), Vivek Kumar(Post Graduate Institute of Medical Education and Research), Rahul Chanchlani(McMaster Children's Hospital), Muhammad Iqbal Abdul Hafidz(Universiti Teknologi MARA), Georges Nakhoul(Cleveland Clinic)
Cited by 66
Related Papers
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k
Chronic kidney disease and the global public health agenda: an international consensus
|Nature Reviews Nephrology|2024|1.1k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Nephrology Dialysis Transplantation|2019|587